Background: Neglected tropical diseases (NTDs) are closely related to poverty and affect
over a billion people in develo** countries. The unmet treatment needs cause high …

Chagas disease is a vector-borne illness caused by the protozoan parasite Trypanosoma
cruzi (T. cruzi). It poses a significant public health burden, particularly in the poorest regions …

The main protease of SARS‐CoV‐2 (Mpro), the causative agent of COVID‐19, constitutes a
significant drug target. A new fluorogenic substrate was kinetically compared to an internally …

New drugs for visceral leishmaniasis that are safe, low cost, and adapted to the field are
urgently required. Despite concerted efforts over the last several years, the number of new …

Fungal infections cause more than 1.5 million deaths a year. Due to emerging antifungal
drug resistance, novel strategies are urgently needed to combat life-threatening fungal …

We identify the Plasmodium falciparum acetyl-coenzyme A synthetase (PfAcAS) as a
druggable target, using genetic and chemical validation. In vitro evolution of resistance with …

The use of chemotherapeutic drugs is the main resource against clinical giardiasis due to
the lack of approved vaccines. Resistance of G. duodenalis to the most used drugs to treat …

In the context of the only available vaccine (DENGVAXIA) that was marketed in several
countries, but poses higher risks to unexposed individuals, the development of antivirals for …

Introduction: Chagas disease (CD) is a neglected disease caused by the protozoan parasite
Trypanosoma cruzi. In terms of novel drug discovery, there has been no progress since the …

Surveillance of drug resistance and the discovery of novel targets—key objectives in the
fight against malaria—rely on identifying resistance-conferring mutations in Plasmodium …